Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

341P - Relationship between muscle mass and quality of life in breast cancer patients who underwent chemotherapy

Date

22 Nov 2020

Session

e-Poster Display Session

Topics

Cytotoxic Therapy

Tumour Site

Breast Cancer

Presenters

Andree Kurniawan

Citation

Annals of Oncology (2020) 31 (suppl_6): S1371-S1377. 10.1016/annonc/annonc364

Authors

A. Kurniawan1, D.A. Halim2, R.D. Hatma3, A. Adisasmita3, N. Sutandyo4, S.S. Panigoro5, F.I. Witjaksono6, D.S. Rivami7, T.Z. Tamin8, R. Sumantri9, C. Jodhinata2, W. Raffaelo2, F. Wijovi2, H. Putri2, O.A. Saroso2, F. Dharmaraja2, N.P.H. Lugito1, C. Cindy2, A. Tancherla2

Author affiliations

  • 1 Internal Medicine Department, Siloam Hospital/Medical faculty of Pelita Harapan University, 15811 - Tangerang/ID
  • 2 Medicine, Faculty of Medicine, Pelita Harapan University, 15811 - Tangerang/ID
  • 3 Epidemiology, Faculty of Public Health, Universitas Indonesia, 11650 - Depok/ID
  • 4 Internal Medicine, Hematology And Medical Oncology, Faculty of Medicine, Universitas Indonesia, Jakarta/ID
  • 5 Surgical Oncology, Faculty of Medicine, Universitas Indonesia, Jakarta/ID
  • 6 Nutrition, Faculty of Medicine, Universitas Indonesia, Jakarta/ID
  • 7 Nutrition, Faculty of Medicine, Pelita Harapan University, 15811 - Tangerang/ID
  • 8 Medical Rehabilitation, Faculty of Medicine, Universitas Indonesia, Jakarta/ID
  • 9 Internal Medicine, Hematology And Medical Oncology, Faculty of Medicine, Universitas Padjajaran, Bandung/ID

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 341P

Background

Lean body mass and low muscle mass are associated with survival, quality of life (QOL), and tolerance to treatment in cancer patients. Most early breast cancer patients were reported in overweight and obese nutrition status. There is still limited data evaluating the relationship between muscle mass and QOL in breast cancer patients, especially in early stages. The aim of this study is to examine the relationship between muscle mass and QOL domain in breast cancer patients before underwent chemotherapy.

Methods

A total of 80 breast cancer patients were enrolled in this study. Women breast cancer patients before they underwent chemotherapy were included in this study. Skeletal muscle mass was measured by bioelectrical impedance analysis, and it was reported as the Skeletal Muscle Index (SMI). QoL was assessed using the EORTC-QLQ-C30. The correlation between SMI and QOL was evaluated using Pearson or Spearmen correlation test based on the normality data.

Results

The mean of age was 47.39+7.07 years old. The median of body mass index (BMI) was 23.15(7.86-47.26) kg/m2. The distribution of BMI for underweight, normo-weight, overweight and obese were 5(6.3%); 33(41.3%); 16(21.1%); and 26(32.6%), respectively. Most patients were in early breast cancer 71 of 80 (88.8%). The median of SMI was 5.72(1.91-12.35). The median of QOL global health status, physical function, role function, emotional function, cognitive function, and social function domain were 66.67(0-100); 93.33(0-133.33); 100(0-133.33); 83.33(33.33-100); 100(16.67-100); and 100(0-100), respectively. The correlation between SMI and QOL global health status, physical function, role function, emotional function, cognitive function, and social function domain were (r 0.194, p 0.085); (r 0.021, p 0.851); (r 0.009, p 0.939); (r 0.061, p 0.588); (r 0.280, p 0.012); and (r 0.078, p 0.490), respectively.

Conclusions

Almost all QOL domains of breast cancer patients before underwent chemotherapy showed good results. The relationship between muscle mass and QOL in breast cancer patients before underwent chemotherapy only showed in the cognitive domain. Further studies need to be done to evaluate the physical activity and protein consumption practice with QoL.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.